Trial Profile

Phase 1/2 Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Patients With Follicular Non-Hodgkin's Lymphoma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 13 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glycopyranosyl lipid adjuvant (Primary) ; Pembrolizumab; Rituximab
Indications Follicular lymphoma
Focus Adverse reactions; Therapeutic Use
Sponsors Immune Design

Most Recent Events

02 Apr 2022 This trial has been completed in France (Date of the global end of the trial : 01-Aug-2019), according to European Clinical Trials Database record.
01 Apr 2022 Results published in the Leukemia and Lymphoma
18 Jun 2020 Status changed from completed to discontinued.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com